Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1996-12-27
|
| pubmed:abstractText |
There are multiple lines of evidence suggesting that human recombinant erythropoietin (rEPO) could influence immune responses by direct effects of rEPO on T or B cells. The present study tested this hypothesis by measuring antibody responses after immunization to tetanus toxoid (TT, a T cell dependent antigen) or pneumococcal capsular polysaccharide antigen (PA, a T cell independent antigen). The patients chosen for this prospective study were chronic hemodialysis patients receiving chronic rEPO therapy, and a comparable group of chronic hemodialysis patients not receiving rEPO therapy. We found that the patients immunized with PA and receiving rEPO therapy (N = 15) had IgG anti-PA responses comparable to that of those not receiving rEPO therapy (N = 15). In contrast, in the patients immunized with TT, those receiving rEPO (N = 15) developed significantly higher IgG anti-TT levels than those not receiving rEPO (N = 14) (time-group interaction P = 0.005). The peak difference between these groups was at two weeks, where the rEPO-treated patients developed a 4.1-fold mean increase in IgG anti-TT level and those not receiving rEPO developed only a 1.4-fold mean increase in IgG anti-TT level (P < 0.01). The difference in immune response to TT in the rEPO compared to the non-rEPO-treated patients could not be explained by differences between the groups in any of the parameters measured at baseline or during the post-immunization period. In conclusion, rEPO therapy increased immune response to TT but not PA, which suggests that rEPO enhances immune response to T cell dependent antigens.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Erythropoietin,
http://linkedlifedata.com/resource/pubmed/chemical/Pneumococcal Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Tetanus Toxoid
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
0085-2538
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
50
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
543-9
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8840284-Adult,
pubmed-meshheading:8840284-Aged,
pubmed-meshheading:8840284-Antibody Formation,
pubmed-meshheading:8840284-Bacterial Vaccines,
pubmed-meshheading:8840284-Erythropoietin,
pubmed-meshheading:8840284-Female,
pubmed-meshheading:8840284-Humans,
pubmed-meshheading:8840284-Immunization,
pubmed-meshheading:8840284-Kidney Failure, Chronic,
pubmed-meshheading:8840284-Male,
pubmed-meshheading:8840284-Middle Aged,
pubmed-meshheading:8840284-Pneumococcal Vaccines,
pubmed-meshheading:8840284-Prospective Studies,
pubmed-meshheading:8840284-Recombinant Proteins,
pubmed-meshheading:8840284-Renal Dialysis,
pubmed-meshheading:8840284-Streptococcus pneumoniae,
pubmed-meshheading:8840284-Tetanus Toxoid,
pubmed-meshheading:8840284-Time Factors
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Effect of chronic human recombinant erythropoietin therapy on antibody responses to immunization in chronic hemodialysis patients.
|
| pubmed:affiliation |
Department of Internal Medicine, Ohio State University, Columbus, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Controlled Clinical Trial,
Research Support, Non-U.S. Gov't
|